Premium
Tri‐docosahexaenoic but not Tri‐eicosapentaenoic Acid‐Rich Emulsions are Neuroprotective after Cerebral Hypoxic‐ Ischemic Injury in Mice
Author(s) -
Mayurasakorn Korapat,
Ten Vadim S.,
Deckelbaum Richard J.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1072.4
Subject(s) - neuroprotection , docosahexaenoic acid , eicosapentaenoic acid , medicine , pharmacology , anesthesia , ischemia , saline , chemistry , biochemistry , fatty acid , polyunsaturated fatty acid
We previously showed a neuroprotective role of n‐3 rich triglyceride (TG) intravenous emulsions (48% eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)) after hypoxicischemic (H/I) injury (ischemic stroke) in 4 different rodent models, while n‐6 TG did not provide neuroprotection. We now questioned the specificity of TGs made with only EPA or DHA on post H/I neuroprotection in C57BL/6J neonatal mice. H/I was induced by right carotid artery ligation followed by exposure to 8% O 2 . Mice then received 2 intraperitoneal administrations of TG containing only DHA (Tri‐DHA) or EPA (Tri‐EPA) at doses of 0.1 and 0.375 g n‐3 TG/kg, administered immediately after H/I at different time points. n‐3 TG (Tri‐DHA) significantly reduced cerebral infarct volume by 47% as compared to saline control ( p < 0.05). Post‐H/I treatment with Tri‐DHA at both doses significantly showed similar reduced (~ 50 %) cerebral infarct volumes when administered at 0, 1, or 2 hr after H/I by 51%, by 46% and 51%, respectively ( p < 0.05), while Tri‐EPA showed no neuroprotective effect. No protective effect from Tri‐DHA was observed with injection at 4 hr after H/I. We conclude that n‐3 TG emulsions rich in DHA in mice are protective against H/I induced cerebral infarction when administered up to 2 hr after H/I injury. Acute Tri‐ DHA emulsion injection may prove to be an effective therapy after ischemic stroke in humans. Supported in part by NIH grants HL 40404 (RJD), NS 056146 (VST)